130 related articles for article (PubMed ID: 16574203)
1. Characterization of neutropenic fever in patients receiving first-line adjuvant chemotherapy for epithelial ovarian cancer.
Sharma S; Rezai K; Driscoll D; Odunsi K; Lele S
Gynecol Oncol; 2006 Oct; 103(1):181-5. PubMed ID: 16574203
[TBL] [Abstract][Full Text] [Related]
2. Identification of risk factors for requiring transfusion during front-line chemotherapy for ovarian cancer.
Hensley ML; Lebeau D; Leon LF; Venkatraman E; Waltzman R; Sabbatini P; Almadrones L; Chi D; Spriggs D
Gynecol Oncol; 2001 Jun; 81(3):485-9. PubMed ID: 11371143
[TBL] [Abstract][Full Text] [Related]
3. Neutropenic enterocolitis in an advanced epithelial ovarian cancer patient treated with paclitaxel/platinum-based chemotherapy: a case report and review of the literature.
Gadducci A; Gargini A; Palla E; Fanucchi A; Genazzani AR
Anticancer Res; 2005; 25(3c):2509-13. PubMed ID: 16080485
[TBL] [Abstract][Full Text] [Related]
4. Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma.
Safra T; Menczer J; Bernstein RM; Shpigel S; Matcejevsky D; Inbar MJ; Golan A; Grisaru D; Levy T
Gynecol Oncol; 2009 Aug; 114(2):215-8. PubMed ID: 19446318
[TBL] [Abstract][Full Text] [Related]
5. Retrospective review of gynecologic oncology patients with therapy-induced neutropenic fever.
McMeekin DS; Gazzaniga C; Berman M; DiSaia P; Manetta A
Gynecol Oncol; 1996 Aug; 62(2):247-53. PubMed ID: 8751557
[TBL] [Abstract][Full Text] [Related]
6. Two for good measure: six versus eight cycles of carboplatin and paclitaxel as adjuvant treatment for epithelial ovarian cancer.
Dizon DS; Weitzen S; Rojan A; Schwartz J; Miller J; Disilvestro P; Gordinier ME; Moore R; Tejada-Berges T; Pires L; Legare R; Granai CO
Gynecol Oncol; 2006 Feb; 100(2):417-21. PubMed ID: 16336992
[TBL] [Abstract][Full Text] [Related]
7. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
Cicin I; Saip P; Eralp Y; Selam M; Topuz S; Ozluk Y; Aydin Y; Topuz E
Gynecol Oncol; 2008 Jan; 108(1):136-40. PubMed ID: 17936342
[TBL] [Abstract][Full Text] [Related]
8. Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group.
Bamias A; Papadimitriou C; Efstathiou E; Rodolakis A; Vlahos G; Voulgaris Z; Bozas G; Fountzilas G; Aravantinos G; Razis E; Gika D; Dimopoulos MA
BMC Cancer; 2006 Sep; 6():228. PubMed ID: 16999858
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study.
Bell J; Brady MF; Young RC; Lage J; Walker JL; Look KY; Rose GS; Spirtos NM;
Gynecol Oncol; 2006 Sep; 102(3):432-9. PubMed ID: 16860852
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy-related myelosuppression as a marker of survival in epithelial ovarian cancer patients.
Rocconi RP; Matthews KS; Kemper MK; Hoskins KE; Barnes MN
Gynecol Oncol; 2008 Feb; 108(2):336-41. PubMed ID: 18006047
[TBL] [Abstract][Full Text] [Related]
11. [Paclitaxel and carboplatin with or without pirarubicin (THP-ADR) as first line chemotherapy in elderly patients].
Nagao S; Okimoto N; Hongo A; Mizutani Y; Kodama J; Yoshinouchi M; Hiramatsu Y; Kudo T
Gan To Kagaku Ryoho; 2003 Feb; 30(2):243-9. PubMed ID: 12610873
[TBL] [Abstract][Full Text] [Related]
12. Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates.
Landrum LM; Gold MA; Moore KN; Myers TK; McMeekin DS; Walker JL
Gynecol Oncol; 2008 Feb; 108(2):342-7. PubMed ID: 17988721
[TBL] [Abstract][Full Text] [Related]
13. Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up.
Akeson M; Zetterqvist BM; Dahllöf K; Brännström M; Horvath G
Acta Obstet Gynecol Scand; 2008; 87(12):1343-52. PubMed ID: 18951208
[TBL] [Abstract][Full Text] [Related]
14. A comparative study on hematological effects of carboplatin plus cyclophosphamide and carboplatin plus paclitaxel chemotherapy for the first line treatment of epithelial ovarian cancer.
Vapattanawong P
J Med Assoc Thai; 2006 Sep; 89(9):1357-61. PubMed ID: 17100369
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
Pignata S; Breda E; Scambia G; Pisano C; Zagonel V; Lorusso D; Greggi S; De Vivo R; Ferrandina G; Gallo C; Perrone F
Crit Rev Oncol Hematol; 2008 Jun; 66(3):229-36. PubMed ID: 18243011
[TBL] [Abstract][Full Text] [Related]
16. Experience with the management of neutropenia in gynecologic cancer patients receiving carboplatin-based chemotherapy.
Markman J; Zanotti K; Webster K; Belinson J; Peterson G; Kulp B; Markman M
Gynecol Oncol; 2004 Feb; 92(2):592-5. PubMed ID: 14766252
[TBL] [Abstract][Full Text] [Related]
17. Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors.
Matulonis UA; Krag KJ; Krasner CN; Atkinson T; Horowitz NS; Lee H; Penson RT
Gynecol Oncol; 2009 Feb; 112(2):394-9. PubMed ID: 19058838
[TBL] [Abstract][Full Text] [Related]
18. Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.
Fotopoulou C; duBois A; Karavas AN; Trappe R; Aminossadati B; Schmalfeldt B; Pfisterer J; Sehouli J;
J Clin Oncol; 2008 Jun; 26(16):2683-9. PubMed ID: 18509180
[TBL] [Abstract][Full Text] [Related]
19. Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients.
Fader AN; von Gruenigen V; Gibbons H; Abushahin F; Starks D; Markman M; Belinson J; Rose P
Gynecol Oncol; 2008 Apr; 109(1):33-8. PubMed ID: 18261784
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease.
Hou JY; Kelly MG; Yu H; McAlpine JN; Azodi M; Rutherford TJ; Schwartz PE
Gynecol Oncol; 2007 Apr; 105(1):211-7. PubMed ID: 17239941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]